Answers are grounded in this paper and cite their sources.
Whether maintenance therapy with bevacizumab (Bev) + pemetrexed (Pem) can achieve greater clinical benefits than Bev or Pem alone for stage IIIB/IV nonsquamous non‐small cell lung cancer (NSCLC) remains unclear. We assessed the antitumour effect and toxicity of maintenance Bev+Pem versus maintenance with single‐agent Bev/Pem in this meta‐analysis.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: